Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Down – Here’s Why

Capricor Therapeutics, Inc. (NASDAQ:CAPR) gapped down before the market opened on Friday . The stock had previously closed at $10.06, but opened at $9.73. Capricor Therapeutics shares last traded at $10.03, with a volume of 641,008 shares changing hands.

Trending Headlines about Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Analyst upgrade provides support. Oppenheimer raised Capricor to Outperform, while another report cited an analyst upgrade as the catalyst for a sharp advance in the shares. The rating suggests the analyst sees potential upside after the stock’s substantial pullback from its 52-week high. Capricor Therapeutics Raised to Outperform at Oppenheimer
• Neutral Sentiment: Rejected shareholder vote narrows Capricor’s strategic options. A rejected vote is pushing the company toward a more limited path, which could affect its financing, corporate strategy, or development plans. The article did not establish whether the outcome creates an immediate financial impact. A Rejected Vote Pushes Capricor Toward a Narrower Path
• Negative Sentiment: Multiple law firms are promoting an investor securities class action. The lawsuit covers investors who purchased CAPR securities from December 17, 2025, through July 26, 2026. Allegations include misleading statements or omissions concerning the HOPE-3 trial’s pre-specified statistical analysis plan and FDA compliance. Investors have until September 28, 2026, to seek lead-plaintiff status; the allegations have not been proven. Capricor Securities Class Action Deadline Notice
• Negative Sentiment: Recent operating disclosures add to uncertainty. Investor-rights firms highlighted Capricor’s second-quarter earnings release and conference call, including the lack of a management question-and-answer session with analysts. Separately, the company’s latest reported quarterly EPS missed consensus expectations, reinforcing concerns about execution and cash needs while its pipeline advances. Capricor Q2 Earnings and Securities Class Action Update

Analysts Set New Price Targets

Several research firms have weighed in on CAPR. Alliance Global Partners lowered shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price on the stock. in a report on Tuesday, July 28th. Maxim Group lowered shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Oppenheimer upgraded shares of Capricor Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday. Wall Street Zen downgraded Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Finally, Roth Capital lowered Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price on the stock. in a report on Monday, July 27th. Two research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $29.15.

Capricor Therapeutics Stock Down 3.8%

The company’s fifty day moving average price is $14.83 and its two-hundred day moving average price is $24.41. The company has a market cap of $562.80 million, a price-to-earnings ratio of -3.95 and a beta of 0.54.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.11). On average, equities research analysts predict that Capricor Therapeutics, Inc. will post -1.72 earnings per share for the current fiscal year.

Insider Transactions at Capricor Therapeutics

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 24,100 shares of Capricor Therapeutics stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $30.38, for a total value of $732,158.00. Following the sale, the chief financial officer owned 11,223 shares of the company’s stock, valued at $340,954.74. This trade represents a 68.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last three months, insiders sold 25,000 shares of company stock worth $759,158. 9.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Capricor Therapeutics

A number of institutional investors have recently modified their holdings of the company. California State Teachers Retirement System grew its holdings in shares of Capricor Therapeutics by 2,261.8% during the second quarter. California State Teachers Retirement System now owns 1,528,478 shares of the biotechnology company’s stock worth $36,806,000 after buying an additional 1,463,762 shares in the last quarter. Montanova Capital LLC lifted its stake in Capricor Therapeutics by 7.2% in the 2nd quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company’s stock valued at $98,554,000 after acquiring an additional 274,184 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in Capricor Therapeutics in the 2nd quarter valued at approximately $3,895,000. Glenmede Trust Co. NA boosted its position in Capricor Therapeutics by 13.2% during the 1st quarter. Glenmede Trust Co. NA now owns 36,330 shares of the biotechnology company’s stock worth $1,104,000 after acquiring an additional 4,240 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in Capricor Therapeutics by 672.0% during the 1st quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock worth $12,631,000 after acquiring an additional 361,664 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.